PropertyValue
?:abstract
  • Bacillus Calmette-GuĂ©rin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
?:creator
?:doi
  • 10.1186/s12931-020-01439-4
?:doi
?:journal
  • Respir_Res
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/033f5ab05b22f2e945306b287550da393500b585.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7351640.xml.json
?:pmcid
?:pmid
?:pmid
  • 32653040.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19
?:type
?:year
  • 2020-07-11

Metadata

Anon_0  
expand all